Literature DB >> 21747398

Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.

J Hirvonen1, R S Goodwin, C-T Li, G E Terry, S S Zoghbi, C Morse, V W Pike, N D Volkow, M A Huestis, R B Innis.   

Abstract

Chronic cannabis (marijuana, hashish) smoking can result in dependence. Rodent studies show reversible downregulation of brain cannabinoid CB(1) (cannabinoid receptor type 1) receptors after chronic exposure to cannabis. However, whether downregulation occurs in humans who chronically smoke cannabis is unknown. Here we show, using positron emission tomography imaging, reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in human subjects who chronically smoke cannabis. Downregulation correlated with years of cannabis smoking and was selective to cortical brain regions. After ∼4 weeks of continuously monitored abstinence from cannabis on a secure research unit, CB(1) receptor density returned to normal levels. This is the first direct demonstration of cortical cannabinoid CB(1) receptor downregulation as a neuroadaptation that may promote cannabis dependence in human brain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21747398      PMCID: PMC3223558          DOI: 10.1038/mp.2011.82

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  40 in total

Review 1.  Signaling pathways involved in the development of cannabinoid tolerance.

Authors:  Billy R Martin; Laura J Sim-Selley; Dana E Selley
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819

2.  Bimodal control of stimulated food intake by the endocannabinoid system.

Authors:  Luigi Bellocchio; Pauline Lafenêtre; Astrid Cannich; Daniela Cota; Nagore Puente; Pedro Grandes; Francis Chaouloff; Pier Vincenzo Piazza; Giovanni Marsicano
Journal:  Nat Neurosci       Date:  2010-02-07       Impact factor: 24.884

Review 3.  International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors:  A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

4.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil.

Authors:  M S Gandelman; R M Baldwin; S S Zoghbi; Y Zea-Ponce; R B Innis
Journal:  J Pharm Sci       Date:  1994-07       Impact factor: 3.534

5.  Clinical relevance of cannabis tolerance and dependence.

Authors:  R T Jones; N L Benowitz; R I Herning
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

Review 6.  Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids.

Authors:  Laura J Sim-Selley
Journal:  Crit Rev Neurobiol       Date:  2003

7.  Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.

Authors:  A Oviedo; J Glowa; M Herkenham
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

8.  Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.

Authors:  R B Innis; R T Malison; M al-Tikriti; P B Hoffer; E H Sybirska; J P Seibyl; S S Zoghbi; R M Baldwin; M Laruelle; E O Smith
Journal:  Synapse       Date:  1992-03       Impact factor: 2.562

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.

Authors:  Christopher S Breivogel; Susan M Scates; Irina O Beletskaya; Olivia B Lowery; Mario D Aceto; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-01-17       Impact factor: 4.432

View more
  213 in total

1.  THC and CBD blood and brain concentrations following daily administration to adolescent primates.

Authors:  S L Withey; J Bergman; M A Huestis; S R George; B K Madras
Journal:  Drug Alcohol Depend       Date:  2020-06-18       Impact factor: 4.492

2.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

3.  Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography.

Authors:  J Hirvonen; P Zanotti-Fregonara; J C Umhau; D T George; D Rallis-Frutos; C H Lyoo; C-T Li; C S Hines; H Sun; G E Terry; C Morse; S S Zoghbi; V W Pike; R B Innis; M Heilig
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

Review 4.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

5.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

6.  Emotion regulation deficits in regular marijuana users.

Authors:  Kaeli Zimmermann; Christina Walz; Raissa T Derckx; Keith M Kendrick; Bernd Weber; Bruce Dore; Kevin N Ochsner; René Hurlemann; Benjamin Becker
Journal:  Hum Brain Mapp       Date:  2017-05-31       Impact factor: 5.038

Review 7.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

8.  Cannabis use and neurocognitive functioning in a non-clinical sample of users.

Authors:  April D Thames; Natalie Arbid; Philip Sayegh
Journal:  Addict Behav       Date:  2014-02-06       Impact factor: 3.913

9.  ΔFosB induction correlates inversely with CB₁ receptor desensitization in a brain region-dependent manner following repeated Δ⁹-THC administration.

Authors:  Matthew F Lazenka; Dana E Selley; Laura J Sim-Selley
Journal:  Neuropharmacology       Date:  2013-09-30       Impact factor: 5.250

10.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.